Analyst Ratings for Covidien Ltd (cov)
cov Rating Summary
cov Price Target Summary
- Highest: $75.00 (Jefferies)
- Lowest: $53.00 (Goldman Sachs)
- Average: $65.75
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$65.75 (-0%)
Avg. $ Target:
$65.75 (-0%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/6/2013 | Atlantic Equities | New Coverage | Overweight (N/A) |
75.00 (N/A) |
64.71 | 65.77 | 1.64% | Details |
| 11/20/2012 | Brean Capital | New Coverage | Buy (N/A) |
66.00 (N/A) |
56.75 | 65.77 | 15.89% | Details |
| 4/25/2012 | Raymond James | New Coverage | Strong Buy (N/A) |
N/A (N/A) |
54.19 | 65.77 | 21.37% | Details |
| 3/13/2012 | William Blair | New Coverage | Outperform (N/A) |
N/A (N/A) |
52.23 | 65.77 | 25.92% | Details |
| 1/12/2012 | Goldman Sachs » Updated 2/3/2012 |
Downgrade | Neutral (N/A) |
53.00 (N/A) |
46.17 | 65.77 | 42.45% | Details |
| 10/5/2011 | Credit Agricole | New Coverage | Buy (N/A) |
57.00 (N/A) |
42.98 | 65.77 | 53.02% | Details |
| 9/9/2011 | Citi | New Coverage | Buy (N/A) |
N/A (N/A) |
49.71 | 65.77 | 32.31% | Details |
| 8/10/2011 | Caris & Co. | Upgrade | Buy (N/A) |
64.00 (N/A) |
47.06 | 65.77 | 39.76% | Details |
| 3/31/2011 | Susquehanna | New Coverage | Positive (N/A) |
N/A (N/A) |
52.11 | 65.77 | 26.21% | Details |
| 9/10/2010 | Deutsche Bank » Updated 4/12/2013 |
New Coverage | Buy (N/A) |
74.00 (70.00) |
36.70 | 65.77 | 79.21% | Details |
| 7/19/2010 | Morgan Keegan | Upgrade | Outperform (N/A) |
N/A (N/A) |
40.03 | 65.77 | 64.3% | Details |
